润都股份：奥美沙坦酯氨氯地平片获药品注册证书

Core Viewpoint - The company has received a drug registration certificate from the National Medical Products Administration for a new medication, Amlodipine Besylate and Olmesartan Medoxomil Tablets, which is aimed at treating primary hypertension [1] Group 1 - The new drug is indicated for adult patients whose blood pressure control is inadequate with either Olmesartan Medoxomil or Amlodipine alone [1] - Each tablet contains 20mg of Olmesartan Medoxomil and 5mg of Amlodipine Besylate [1] - The approval of this drug enhances the company's product portfolio in the sartans category, which is expected to improve its market competitiveness in the cardiovascular disease treatment sector [1] Group 2 - The introduction of this medication is anticipated to have a positive impact on the company's future operating performance [1]